Aytu BioPharma, Inc.: updates and filings

AYTUNASDAQHealthcare · Pharmaceutical Preparations

Price

$2.66

November 19, 2026Market cap $51M

What Ploutos Investor adds for Aytu BioPharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from FY2014
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 46% since Nov 16, 2026, when the 10-Q these figures come from was filed ($1.82 then, $2.66 on Nov 19, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 84 daysAround Feb 12, 2027 · for Q2 2027

last Nov 16, 2026next Feb 12, 2027

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Sep 22, 2026 latest annualNov 16, 2026 latest quarterly
  • Nov 16, 2026Filing
    FormSC TO-C
  • Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 16, 2026Results of operations
    Form8-K
  • Nov 16, 2026FORM 425
    Form425
  • Nov 16, 2026Material agreement entered, Regulation FD disclosure
    Form8-K
  • Oct 27, 2026Additional annual meeting material
    FormDEFA14A
  • Oct 22, 2026Annual meeting proxy statement
    FormDEF 14A
  • Sep 22, 2026Annual reportfor the period to Jun 30, 2026
    Form10-K
  • Sep 22, 2026Results of operations
    Form8-K
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jun 25, 2026Material agreement ended
    Form8-K
  • May 13, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 13, 2026Results of operations
    Form8-K
  • Apr 2, 2026Material agreement entered, results of operations, unregistered sale of shares, change to shareholders' rights
    Form8-K
  • Feb 17, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 3, 2026Quarterly reportfor the period to Dec 31, 2025
    Form10-Q
  • Feb 3, 2026Results of operations
    Form8-K
  • Jan 20, 2026Regulation FD disclosure
    Form8-K
  • Dec 10, 2025Shareholder vote
    Form8-K
  • Nov 14, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Nov 13, 2025Results of operations
    Form8-K
  • Nov 12, 2025Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 24, 2025Annual report to shareholdersfor the period to Jun 30, 2025
    FormARS

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 11, 2007. Of its note and share prospectuses (424B, FWP), the newest 40 of 71.

The full analysis

What do Aytu BioPharma's filings show?

The filings are where every one of Aytu BioPharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.